Blocking the CD39/CD73 pathway synergizes with anti-CD20 bispecific antibody in nodal B-cell lymphoma

Bispecific antibodies (BsAb) have emerged as a leading treatment modality in patients suffering from B-cell non-Hodgkin’s lymphoma (B-NHL). However, treatment failure is common and may potentially be attributed to pre-existing or emerging T-cell exhaustion. CD39 catalyzes—together with CD73—the hydr...

詳細記述

書誌詳細

出版年:	Journal for ImmunoTherapy of Cancer
主要な著者:	Carsten Müller-Tidow, Peter Dreger, Joseph Kauer, Wolfgang Huber, Clara Kolbe, Berit Brinkmann, Sascha Dietrich, Tobias Roider
フォーマット:	論文
言語:	英語
出版事項:	BMJ Publishing Group 2025-01-01
オンライン･アクセス:	https://jitc.bmj.com/content/13/1/e009245.full